Jim Cramer says the best is yet to come at Oracle — plus, his thoughts on 4 more stocks

  • 📰 CNBC
  • ⏱ Reading Time:
  • 22 sec. here
  • 24 min. at publisher
  • 📊 Quality Score:
  • News: 89%
  • Publisher: 72%

Media News

Health Care Industry,Pharmaceuticals,Retail Industry

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio.

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Oracle : The tech giant had a mixed quarter. But it announced new artificial intelligence partnerships with Alphabet 's Google and Microsoft -backed OpenAI. Oracle also reported strong RPO, short for remaining performance obligation. RPO is what contracted customers are expected to pay in the future and the backlog of business.

"This is a momentum stock so it's not necessarily going to give up the ghost here," Cramer said. "But it is expensive versus its cohorts." Johnson & Johnson : The company reached a $700 million settlement with states over the marketing of its talc-based baby powder. This is a positive, Cramer said. But he added that J & J is a health-care staple stock and it's not going to run here.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in BUSİNESS
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030AstraZeneca CEO Pascal Soriot discussed his company’s ambitious revenue goal with CNBC’s Jim Cramer.
Source: NBCNewYork - 🏆 270. / 63 Read more »